SCHEMBL30714645

SCHEMBL30714645

Cc1ncsc1COc1ccc2nn(C)c(C(=O)NCCN3CCOC3=O)c2c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.41
HPGDS O60760 1/20 0.35
SLC8A1 P32418 3/20 0.34
NQO2 P16083 1/20 0.33
POLB P06746 4/20 0.33
MAPT P10636 4/20 0.33
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 1/20 0.33
GLA P06280 1/20 0.33
PLAT P00750 1/20 0.33
PDE10A Q9Y233 1/20 0.33
LMNA P02545 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
KMT2A Q03164 1/20 0.32
NTRK1 P04629 1/20 0.32
TGFBR1 P36897 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714710 0.85 NAAA (0.44) SCN9APOLBMAPTALDH1A1KDM4E
SCHEMBL30714743 0.84 SCN9A (0.42) SCN9AHPGDSNQO2POLBMAPT
SCHEMBL30656271 0.83 SCN9A (0.38) SCN9AHPGDSSLC8A1NQO2POLB
SCHEMBL30714616 0.80 NPC1 (0.40) HPGDSTGFBR1
SCHEMBL30714703 0.80 ALDH1A1 (0.46) ALDH1A1KDM4ELMNAKMT2A
SCHEMBL30714746 0.79 SCN9A (0.45) SCN9AHPGDSSLC8A1NQO2POLB
SCHEMBL30714585 0.79 SLC6A5 (0.42) ALDH1A1KDM4ELMNA
SCHEMBL31539873 0.79 SLC8A1 (0.34) SLC8A1POLBMAPTALDH1A1KDM4E
SCHEMBL30714671 0.78 IKBKE (0.34) ALDH1A1KDM4EPDE10AKMT2A
SCHEMBL26696049 0.78 PLA2G2A (0.36) POLBMAPTALDH1A1KDM4EPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 SCN9A 518/4885HPGDS 671/4885SLC8A1 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.